Industry Insights Logo

Putting a Human Face on 340B

Glen Pietrandoni headshot

SPONSORED CONTENT

Let me ask you something: Do you remember what was going on with the 340B program in the early 1990s?

Perhaps I should phrase that question another way, because those of us on the advocacy side can easily cite the fact that the program was

Read More »

AstraZeneca Stops Voluntary 340B Pricing on Orphan Drugs to Rural and Cancer Hospitals

AstraZeneca wordmark building-mounted sign
Effective June 1, AstraZeneca will stop offering voluntary 340B pricing on orphan drugs to critical access hospitals, sole community hospitals, rural referral centers, and free-standing cancer hospitals.

Drug manufacturer AstraZeneca effective June 1 will stop offering voluntary 340B pricing on its orphan drugs to critical access hospitals, sole community hospitals, rural referral centers, and free-standing cancer hospitals, the company said yesterday.

“AstraZeneca is making this change to

Read More »

California 340B Health Centers Blast CMS in Court Over its Role in State Medicaid Drug Benefit Transfer

United States District Court, Sacramento high-rise building
California 340B health centers' suit against the state's transfer of Medicaid managed care drug benefits to Medicaid fee for service is being heard at the Robert T. Matsui United States Courthouse in Sacramento.

California health centers asked a federal district judge in late April to deny the U.S. Centers for Medicare & Medicaid Services (CMS) motion to dismiss the health centers’ claims against CMS arising over the state’s transfer of Medicaid managed care

Read More »

Non-Hospital Infusion Centers See a Path to 340B Reform that Runs Through the States

copies of Worcester Business Journal online article and Infusion Access Foundation letter
Infusion Access Foundation's state level 340B outreach includes appeals to Massachusetts' attorney general last month (left) and California's last November (right).

A foundation linked to a trade group that represents non-hospital infusion centers is working to enlist state attorneys general and legislators to push for major 340B program changes at the federal level.

The National Infusion Center Association (NICA) is the

Read More »

340B INDUSTRY LEADER SPOTLIGHT

Patti Schnieder, Vice President, Caravan Health

Patti Schnieder portrait
Patti Schnieder, VP, Caravan Health

Q: Where did you grow up?

I grew up in Maryland. We lived in a rural area, Finksburg, and spent a lot of time at the beach in Ocean City.

Q: Where did you go to college/graduate school?

I attended a few colleges and graduated with a Liberal Arts degree in English from Towson State

Read More »

Sen. Grassley Presses HHS OIG to Punish Drug Makers Over Denials of 340B Pricing

Sen. Chuck Grassley (R-IA) headshot
U.S. Sen. Chuck Grassley (R-Iowa) wants to know if HHS will impose civil monetary penalties on drug companies that deny 340B pricing over multiple contract pharmacy.

Senate Finance Committee ranking Republican Chuck Grassley (Iowa) yesterday asked the U.S. Health and Human Services Department of Inspector General (OIG) if it plans to punish seven drug companies over their denials of 340B pricing when hospitals, health centers, and

Read More »

Merck Adds 45-Day Time Limit on Replenishment Orders to its 340B Contract Pharmacy Policy

Merck and U.S. flags
Merck has imposed 45-day time limit on replenishment orders under its restrictions on 340B pricing when covered entities use contract pharmacies.

Merck is the latest drug company among the 16 that restrict 340B pricing when covered entities use contract pharmacies to impose a 45-day time limit on replenishment orders under its policy.

Merck disclosed the change last week in the same letter

Read More »

Appeals Court Consolidates AstraZeneca, Sanofi, and Novo Nordisk’s 340B Contract Pharmacy Cases

Seal of the United States Court of Appeals for the Third Circuit
The U.S. Third Circuit Court of Appeals has decided to hear and rule on AstraZeneca, Sanofi, and Novo Nordisk’s 340B contract pharmacy litigation together.

A federal appeals court in Philadelphia, as expected, has decided to consider and rule on AstraZeneca’s 340B contract pharmacy lawsuit in tandem with Sanofi and Novo Nordisk’s 340B contract pharmacy cases.

The U.S. Third Circuit Court of Appeals announced the

Read More »

Sen. Manchin Endorses 340B Ally McKinley in Tight GOP Primary Race

Sen. Joe Manchin (D-WV) and Rep. David McKinley (R-WV) headshots
Conservative Democratic U.S. Sen. Joe Manchin has endorsed moderate Republican Rep. David McKinley in West Virginia's GOP congressional primary election next week against Rep. Alex Mooney, who is backed by ex-President Trump.

Conservative Democratic U.S. Sen. Joe Manchin (W.Va.) has endorsed and appeared in a campaign advertisement for Republican Rep. David McKinley (W.Va.), a moderate being challenged for re-election by a candidate endorsed by ex-President Donald Trump.

The GOP primary between McKinley

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live